Nouscom

Nouscom is a leading biotechnology research company dedicated to redefining cancer immunotherapy through innovative approaches and a proprietary viral vector platform. Specializing in the development of both off-the-shelf and personalized neoantigen immunotherapies, Nouscom aims to activate robust and durable T cell responses in cancer patients. The company's commitment to advancing cancer treatment is evident in its lead program, NOUS-209, which is progressing toward registration for cancer interception in Lynch Syndrome carriers, offering a transformative opportunity for these patients. This program has garnered positive regulatory feedback, with a global registrational trial anticipated to launch in H1 2026. Nouscom’s dedication to innovation extends to its second clinical program, NOUS-PEV, a personalized immunotherapy for advanced solid tumors. This program has already demonstrated clinical responses in metastatic melanoma patients and is supported by a fully automated GMP manufacturing process, enabling scalable delivery within 8 weeks. Nouscom is located at Bäumleingasse 18, BS, Basel-City 4051, CH.

Nouscom stands at the forefront of the next generation of cancer immunotherapy, supported by leading life sciences investors. The company’s clinically validated platform, tested in over 170 patients, offers unmatched immunogenicity, scalability, and safety. With a focus on safe, scalable, and effective solutions, Nouscom is dedicated to improving patient outcomes and driving advancements in cancer care. The information here will be completed soon with the support of the company’s management.

We invite the management team at Nouscom to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work in biotechnology research.